📣 VC round data is live. Check it out!
- Public Comps
- Paxman
Paxman Valuation Multiples
Discover Paxman's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like CVRx, MEZOO, Laxmi Dental, EBR Systems and more.
Paxman Overview
About Paxman
Paxman AB is a Sweden based company engaged in the development of PAXMAN Scalp Cooling System that is used to minimize hair loss in connection with chemotherapy treatment. The company offers a stand-alone, mobile electric cooling unit, which is a liquid-based cooling system that cools down the patient's scalp through the silicone hat. Geographically the company markets its product to Great Britain, Scandinavian countries, the Netherlands, Belgium, and Australia.
Founded
2016
HQ

Employees
105
Website
Financials (LTM)
EV
$130M
Valuation Multiples
Start free trialPaxman Financials
Paxman reported last 12-month revenue of $39M and EBITDA of $5M.
In the same LTM period, Paxman generated $25M in gross profit, $5M in EBITDA, and $307K in net income.
Revenue (LTM)
Paxman P&L
In the most recent fiscal year, Paxman reported revenue of $35M and EBITDA of $3M.
Paxman is unprofitable as of last fiscal year, with gross margin of 65%, EBITDA margin of 9%, and net margin of (5%).
Financial data powered by Morningstar, Inc.
Paxman Stock Performance
Paxman has current market cap of $141M, and enterprise value of $130M.
Market Cap Evolution
Paxman's stock price is $6.04.
Paxman share price decreased by 0.5% in the last 30 days, and by 30.5% in the last year.
Paxman has an EPS (earnings per share) of $-0.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $130M | $141M | 0.3% | -0.5% | 15.1% | -30.5% | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPaxman Valuation Multiples
Paxman trades at 3.3x EV/Revenue multiple, and 25.7x EV/EBITDA.
EV / Revenue (LTM)
Paxman Financial Valuation Multiples
As of June 3, 2026, Paxman has market cap of $141M and EV of $130M.
Paxman has a P/E ratio of 457.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Paxman Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Paxman Margins & Growth Rates
Paxman grew revenue by 28% and EBITDA by 138% in the last fiscal year.
In the most recent fiscal year, Paxman reported gross margin of 65%, EBITDA margin of 9%, and net margin of (5%).
Paxman Margins
Paxman Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Paxman Operational KPIs
Paxman's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Paxman's Rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Paxman's Rule of X is 97% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Paxman Competitors
Paxman competitors include CVRx, MEZOO, Laxmi Dental, EBR Systems, BICO Group, Viromed Medical, Nyxoah, Hyperfine, Curiosis and SANUWAVE Health.
Most Paxman public comparables operate across Medical Devices, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.3x | 2.2x | (3.0x) | (3.0x) | |||
| - | 19.8x | - | - | |||
| 4.4x | 4.2x | 26.2x | 25.9x | |||
| 108.1x | 22.6x | (4.1x) | (3.5x) | |||
| 0.7x | 0.7x | 61.0x | 26.4x | |||
| - | 6.4x | (600.2x) | 44.1x | |||
| 12.2x | 5.8x | (1.6x) | (1.6x) | |||
| 9.0x | 7.5x | (3.5x) | (3.6x) | |||
This data is available for Pro users. Sign up to see all Paxman competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Paxman
Paxman has acquired 1 company to date.
Last acquisition by Paxman was on May 8th 2025. Paxman acquired Dignitana for $15M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Paxman
| Description | Dignitana is a Lund-based medical device company marketing the FDA-cleared DigniCap scalp cooling system to prevent chemotherapy-induced alopecia. Clinical trials across breast, ovarian, and other cancers show 80 percent of patients retaining sufficient hair to avoid wigs. Deployed in over 250 U.S. oncology centers and 1,000 worldwide, the system regulates scalp temperature during infusions. |
| HQ Country | |
| HQ City | Lund |
| Deal Date | 8 May 2025 |
| Valuation | $15M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Paxman acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Paxman
| When was Paxman founded? | Paxman was founded in 2016. |
| Where is Paxman headquartered? | Paxman is headquartered in Sweden. |
| How many employees does Paxman have? | As of today, Paxman has over 105 employees. |
| Is Paxman publicly listed? | Yes, Paxman is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Paxman? | Paxman trades under PAX ticker. |
| When did Paxman go public? | Paxman went public in 2017. |
| Who are competitors of Paxman? | Paxman main competitors include CVRx, MEZOO, Laxmi Dental, EBR Systems, BICO Group, Viromed Medical, Nyxoah, Hyperfine, Curiosis, SANUWAVE Health. |
| What is the current market cap of Paxman? | Paxman's current market cap is $141M. |
| What is the current revenue of Paxman? | Paxman's last 12 months revenue is $39M. |
| What is the current revenue growth of Paxman? | Paxman revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of Paxman? | Current revenue multiple of Paxman is 3.3x. |
| What is the current EBITDA of Paxman? | Paxman's last 12 months EBITDA is $5M. |
| What is Paxman's EBITDA margin? | Paxman's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Paxman? | Current EBITDA multiple of Paxman is 25.7x. |
| What is the current FCF of Paxman? | Paxman's last 12 months FCF is $609K. |
| What is Paxman's FCF margin? | Paxman's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Paxman? | Current FCF multiple of Paxman is 212.8x. |
| How many companies Paxman has acquired to date? | As of June 2026, Paxman has acquired 1 company. |
| What was the largest acquisition by Paxman? | $15M acquisition of Dignitana on 8th May 2025 was the largest M&A Paxman has done to date. |
| What companies Paxman acquired? | Paxman acquired Dignitana. |
| In how many companies Paxman has invested to date? | Paxman hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Paxman
Lists including Paxman
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
